Viatris Swats Away Concerns Over Divestment Valuations

As US-Based Firm Updates On Glatiramer And Botox Biosimilar

 
• By Dean Rudge
  
Dollars (David Wall/Alamy Stock Photo)
Rising rates are no concern to Viatris currently • Source: Shutterstock (Alamy Stock Photo)
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Strategy

More from Business